治疗晚期或转移性尿路上皮癌的抗体偶联药物:enfortumab vedotin  

An antibody-drug conjugate in treating advanced or metastatic urothelial cancer: enfortumab vedotin

作　　者：杨君义 YANG Jun-yi(Department of Pharmacy,Central Hospital of Linyi City,Linyi SHANDONG 276400,China)

机构地区：[1]临沂市中心医院药学部,山东临沂276400

出　　处：《中国新药与临床杂志》2021年第2期102-104,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：enfortumab vedotin为一种抗体偶联药物,可与nectin-4结合释放出小分子细胞毒药物单甲基奥瑞他汀E。单甲基奥瑞他汀E具有抗有丝分裂的作用,能作用于微管蛋白抑制肿瘤生长。enfortumab vedotin可用于治疗晚期或转移性尿路上皮癌。常见不良反应有疲劳、外周神经病变、食欲下降、皮疹等。Enfortumab vedotin is an antibody-drug conjugate that selectively acts on nectin-4 and releases the small molecule cytotoxic drug monomethyl auristatin E. Monomethyl auristatin E has anti-mitotic effect and it can act on tublin to inhibit tumor growth. Enfortumab vedotin was indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. It’s common adverse reactions included fatigue, peripheral neuropathy, decreased appetite, rash and so on.

关 键 词：免疫轭合物 尿道上皮 肿瘤 连接蛋白 enfortumab vedotin 

分 类 号：R979.1[医药卫生—药品]